| Daclizumab |
Website Links For Daclizumab |
Information AboutDaclizumab |
| CATEGORIES ABOUT DACLIZUMAB | |
| immunosuppressive agents | |
| monoclonal antibodies | |
|
It is given in multiple doses, the first 1 hour before the transplant operation and 5 further doses given at two week intervals after the transplant. These saturate the receptors and prevent T cell activation and thus prevent formation of Antibodies against the transplant. Like the similar drug Basiliximab , daclizumab reduces the incidence and severity of acute rejection in kidney transplantation without increasing the incidence of Opportunistic Infections . Daclizumab can also be used in place of a calcineurin-inhibitor ( Cyclosporine or Tacrolimus ) in the early phase after kidney transplantation when the kidney is recovering and vulnerable to calcineurin-inhibitor toxicity. This has been shown to be beneficial in Non-heart Beating Donor kidney transplantation. In the United Kingdom , the National Institute For Health And Clinical Excellence has recommended its use be considered for all kidney transplant recipients. |
|
|